Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

689 - NKG2D enhances chemosensitivity to cisplatin in patients with extensive small cell lung cancer by up-regulating NF-_2

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Ruirui Si

Citation

Annals of Oncology (2018) 29 (suppl_9): ix23-ix27. 10.1093/annonc/mdy430

Authors

R. Si, G. Yang, X. Tang

Author affiliations

  • Department Of Immunology, Zhengzhou University, 450006 - Zhengzhou/CN
More

Resources

Abstract 689

Background

Extensive small cell lung cancer (SCLC) still does not have a method to significantly improve the efficacy of chemotherapy, often resulting in chemotherapy failure due to rapid drug resistance. Recently, the role of immunization in the treatment of cancer has been paid more and more attention, so the role of immune-related genes in chemotherapy needs further research. In this study, the effects of NKG2D on chemotherapy to etoposide combined with cisplatin were studied, and the mechanism was researched.

Methods

152 patients with extensive SCLC diagnosed by pathology were included in the study. Tumor tissues were subjected to NKG2D immunohistochemistry and quantified. Then the patient's NKG2D expression level was correlated analyzed with etoposide combined with cisplatin chemotherapy asymptomatic survival time (PFS) and overall survival time (OS). Through the whole-genome transcriptome sequencing, the possible pathways of NKG2D were found, and high-expression and interfering NCI-H446 cell lines were constructed for pathway validation.

Results

The expression level of NKG2D in 152 tumor tissues showed a normal distribution. Correlation analysis showed that it had a significant positive correlation with PFS (R2=0.283, P = 0.006) and OS (R2=0.235, P = 0.022). In addition, we found that the top 20 patients with the highest NKG2D expression had a longer median PFS than the lowest 20 patients for 3.5 months (9.2 months vs. 5.7 months, P < 0.05). It is worth noting that the median OS is more obviously extended (23.3 months v.s. 10.4 months, P < 0.01). Transcriptome detection of tumor tissues in patients with high expression of NKG2D revealed that NKG2D up-regulated NKG2DLs, apoptotic genes, DNA damage repair genes and nuclear factor (NF) family genes. In vitro, IC50 value to cisplatin of NKG2D over-expressed NCI-H446 cell was significantly lower than control. Then, we interfered with NF-κβ2 and found that it inhibited the chemosensitivity of NKG2D over-expression cell lines to cisplatin.

Conclusions

NKG2D is a predictive and prognostic factor for chemotherapy in patients with extensive small cell lung cancer, possibly be achieved by upregulating NF-κβ2.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Medical Science and Technology Program of Henan Province.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings